Open Access

Roles of DNA damage repair and precise targeted therapy in renal cancer (Review)

  • Authors:
    • Yongchang Lai
    • Zhibiao Li
    • Zechao Lu
    • Hanxiong Zheng
    • Chiheng Chen
    • Can Liu
    • Yafei Yang
    • Fucai Tang
    • Zhaohui He
  • View Affiliations

  • Published online on: October 19, 2022     https://doi.org/10.3892/or.2022.8428
  • Article Number: 213
  • Copyright: © Lai et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The primary subtypes of renal cell carcinoma (RCC) include clear cell, papillary and chromophobe RCC. RCC occurs often due to loss of von Hippel‑Lindau (VHL) and accumulation of lipids and glycogen, and RCC cells may exhibit sensitivity to the disruption of normal metabolism or homologous recombination gene defect. Although the application of molecular‑targeted drugs (tyrosine kinase inhibitors) and immune checkpoint inhibitors has been recommended for the treatment of advanced RCC, more targets of DNA damage repair (DDR) signaling pathway involved in the synthetic lethal effect have been investigated. However, although achievements has been made in the exploration of the roles of DDR genes on RCC progression, their association has not been systematically summarized. Poly (ADP‑ribose) polymerase (PARP) 1 inhibitors are used in tumors with BRCA1/2 DNA repair‑associated mutations. PARP family enzymes perform post‑translational modification functions and participate in DDR and cell death. Inhibitors of PARP, ataxia telangiectasia mutant gene and polymerase θ serve key roles in the treatment of specific RCC subtypes. PARP1 may serve as an important biological marker to predict the therapeutic effect of immune checkpoint inhibitors and evaluate the prognosis of patients with ccRCC with polybromo 1 mutation. Therefore, the roles of DDR pathway on RCC progression or treatment may hold promises for the treatment of certain specific types of RCC.
View Figures
View References

Related Articles

Journal Cover

December-2022
Volume 48 Issue 6

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Lai Y, Li Z, Lu Z, Zheng H, Chen C, Liu C, Yang Y, Tang F and He Z: Roles of DNA damage repair and precise targeted therapy in renal cancer (Review). Oncol Rep 48: 213, 2022
APA
Lai, Y., Li, Z., Lu, Z., Zheng, H., Chen, C., Liu, C. ... He, Z. (2022). Roles of DNA damage repair and precise targeted therapy in renal cancer (Review). Oncology Reports, 48, 213. https://doi.org/10.3892/or.2022.8428
MLA
Lai, Y., Li, Z., Lu, Z., Zheng, H., Chen, C., Liu, C., Yang, Y., Tang, F., He, Z."Roles of DNA damage repair and precise targeted therapy in renal cancer (Review)". Oncology Reports 48.6 (2022): 213.
Chicago
Lai, Y., Li, Z., Lu, Z., Zheng, H., Chen, C., Liu, C., Yang, Y., Tang, F., He, Z."Roles of DNA damage repair and precise targeted therapy in renal cancer (Review)". Oncology Reports 48, no. 6 (2022): 213. https://doi.org/10.3892/or.2022.8428